Generation Bio Co. Financials
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Generation Bio Co. has an operating margin of -715.8%, meaning the company retains $-716 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -2346.9% the prior year.
Generation Bio Co.'s revenue surged 236.9% year-over-year to $19.9M, reflecting rapid business expansion. This strong growth earns a score of 100/100.
Generation Bio Co. has a moderate D/E ratio of 1.68. This balance of debt and equity financing earns a leverage score of 49/100.
With a current ratio of 5.50, Generation Bio Co. holds $5.50 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
While Generation Bio Co. generated -$88.6M in operating cash flow, capex of $2.4M consumed most of it, leaving -$91.0M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Generation Bio Co. passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Generation Bio Co. generates $0.67 in operating cash flow (-$88.6M OCF vs -$131.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
This page shows Generation Bio Co. (GBIO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Generation Bio Co. generated $19.9M in revenue in fiscal year 2024. This represents an increase of 236.9% from the prior year.
Generation Bio Co.'s EBITDA was -$137.5M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 3.1% from the prior year.
Generation Bio Co. generated -$91.0M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 51.2% from the prior year.
Generation Bio Co. reported -$131.7M in net income in fiscal year 2024. This represents a decrease of 4.0% from the prior year.
Generation Bio Co. earned $-1.98 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 1.0% from the prior year.
Generation Bio Co. held $76.3M in cash against $0 in long-term debt as of fiscal year 2024.
Generation Bio Co. had 7M shares outstanding in fiscal year 2024. This represents a decrease of 89.9% from the prior year.
Generation Bio Co.'s operating margin was -715.8% in fiscal year 2024, reflecting core business profitability. This is up 1631.1 percentage points from the prior year.
Generation Bio Co.'s net profit margin was -661.9% in fiscal year 2024, showing the share of revenue converted to profit. This is up 1482.6 percentage points from the prior year.
Generation Bio Co. invested $61.3M in research and development in fiscal year 2024. This represents a decrease of 34.5% from the prior year.
Generation Bio Co. invested $2.4M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 67.5% from the prior year.
GBIO Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.6M+108.4% | $765K-91.2% | $8.7M+108.3% | $4.2M+2.4% | $4.1M+0.8% | $4.1M+41.0% | $2.9M+34.1% | $2.1M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $21.6M+39.6% | $15.5M+0.9% | $15.4M-0.9% | $15.5M-5.5% | $16.4M+14.3% | $14.3M-48.7% | $27.9M+27.7% | $21.9M |
| SG&A Expenses | $12.2M+58.6% | $7.7M-13.2% | $8.8M+2.1% | $8.7M-9.0% | $9.5M-8.8% | $10.4M-22.0% | $13.4M+14.9% | $11.6M |
| Operating Income | -$6.7M+70.7% | -$22.9M-38.0% | -$16.6M+29.5% | -$23.6M-1.1% | -$23.3M+70.0% | -$77.6M-102.1% | -$38.4M-22.5% | -$31.4M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$5.5M+73.6% | -$20.9M-41.4% | -$14.8M+30.8% | -$21.4M-4.6% | -$20.4M+72.6% | -$74.5M-111.8% | -$35.2M-24.5% | -$28.3M |
| EPS (Diluted) | $-0.82+73.7% | $-3.12-1318.2% | $-0.22 | $4.50 | $-3.07-174.1% | $-1.12-111.3% | $-0.53-23.3% | $-0.43 |
GBIO Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $121.9M-32.1% | $179.4M-10.9% | $201.3M-12.9% | $231.2M-12.8% | $265.3M-7.2% | $285.9M-23.7% | $374.8M-1.8% | $381.5M |
| Current Assets | $93.5M-35.8% | $145.5M-11.9% | $165.1M-14.4% | $192.9M-13.6% | $223.3M-1.6% | $226.9M-16.8% | $272.6M-8.5% | $297.8M |
| Cash & Equivalents | $21.9M-55.3% | $49.1M-3.5% | $50.9M-33.3% | $76.3M+167.7% | $28.5M-19.8% | $35.5M-46.5% | $66.4M-28.8% | $93.4M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $391K+52.7% | $256K-81.6% | $1.4M+13.7% | $1.2M-8.5% | $1.3M | N/A | $0 | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $71.3M-43.1% | $125.3M-2.1% | $128.0M-11.7% | $145.0M-3.2% | $149.9M-2.6% | $153.9M-10.3% | $171.6M+14.7% | $149.6M |
| Current Liabilities | $21.0M+8.6% | $19.4M-1.2% | $19.6M-44.1% | $35.1M+16.5% | $30.1M+6.3% | $28.3M-29.1% | $39.9M+21.6% | $32.8M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $50.6M-6.5% | $54.1M-26.2% | $73.3M-14.9% | $86.2M-25.3% | $115.4M-12.6% | $132.0M-35.0% | $203.1M-12.4% | $231.9M |
| Retained Earnings | -$744.3M-0.7% | -$738.8M-2.9% | -$717.8M-2.1% | -$703.0M-5.5% | -$666.4M-3.2% | -$645.9M-13.0% | -$571.4M-6.6% | -$536.2M |
GBIO Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$52.7M-213.0% | -$16.8M+40.7% | -$28.4M-79.7% | -$15.8M+26.7% | -$21.5M+32.1% | -$31.7M-26.9% | -$25.0M-0.3% | -$24.9M |
| Capital Expenditures | $0-100.0% | $459K+86.6% | $246K-34.9% | $378K+2600.0% | $14K-99.3% | $1.9M-58.1% | $4.6M+650.8% | $610K |
| Free Cash Flow | -$52.7M-204.7% | -$17.3M+39.6% | -$28.6M-77.0% | -$16.2M+25.0% | -$21.5M+35.9% | -$33.6M-13.7% | -$29.6M-15.9% | -$25.5M |
| Investing Cash Flow | $25.5M+70.7% | $15.0M+405.6% | $3.0M-95.8% | $70.3M+481.3% | $12.1M+2286.3% | -$553K+71.1% | -$1.9M+92.8% | -$26.6M |
| Financing Cash Flow | -$2K-102.5% | $80K+1242.9% | -$7K-104.9% | $144K-38.5% | $234K+287.2% | -$125K-262.3% | $77K+158.8% | -$131K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
GBIO Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -420.8%+2574.7pp | -2995.6%-2805.2pp | -190.4%+372.3pp | -562.6%+7.1pp | -569.8%+1342.9pp | -1912.6%-577.7pp | -1335.0%+126.2pp | -1461.2% |
| Net Margin | -346.3%+2388.7pp | -2735.0%-2565.3pp | -169.7%+340.9pp | -510.6%-11.1pp | -499.4%+1337.0pp | -1836.4%-613.9pp | -1222.6%+94.6pp | -1317.2% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -4.5%+7.1pp | -11.7%-4.3pp | -7.3%+1.9pp | -9.3%-1.6pp | -7.7%+18.4pp | -26.1%-16.7pp | -9.4%-2.0pp | -7.4% |
| Current Ratio | 4.44-3.1 | 7.51-0.9 | 8.43+2.9 | 5.50-1.9 | 7.42-0.6 | 8.01+1.2 | 6.83-2.2 | 9.07 |
| Debt-to-Equity | 1.41-0.9 | 2.32+0.6 | 1.75+0.1 | 1.68+0.4 | 1.30+0.1 | 1.17+0.3 | 0.84+0.2 | 0.65 |
| FCF Margin | -3304.9%-1045.2pp | -2259.7%-1931.8pp | -327.9%+58.0pp | -385.9%+140.8pp | -526.7%+301.4pp | -828.2%+198.9pp | -1027.0%+161.5pp | -1188.5% |
Similar Companies
Frequently Asked Questions
What is Generation Bio Co.'s annual revenue?
Generation Bio Co. (GBIO) reported $19.9M in total revenue for fiscal year 2024. This represents a 236.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Generation Bio Co.'s revenue growing?
Generation Bio Co. (GBIO) revenue grew by 236.9% year-over-year, from $5.9M to $19.9M in fiscal year 2024.
Is Generation Bio Co. profitable?
No, Generation Bio Co. (GBIO) reported a net income of -$131.7M in fiscal year 2024, with a net profit margin of -661.9%.
What is Generation Bio Co.'s earnings per share (EPS)?
Generation Bio Co. (GBIO) reported diluted earnings per share of $-1.98 for fiscal year 2024. This represents a -1.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Generation Bio Co.'s EBITDA?
Generation Bio Co. (GBIO) had EBITDA of -$137.5M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Generation Bio Co.'s operating margin?
Generation Bio Co. (GBIO) had an operating margin of -715.8% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Generation Bio Co.'s net profit margin?
Generation Bio Co. (GBIO) had a net profit margin of -661.9% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Generation Bio Co.'s free cash flow?
Generation Bio Co. (GBIO) generated -$91.0M in free cash flow during fiscal year 2024. This represents a -51.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Generation Bio Co.'s operating cash flow?
Generation Bio Co. (GBIO) generated -$88.6M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Generation Bio Co.'s total assets?
Generation Bio Co. (GBIO) had $231.2M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Generation Bio Co.'s capital expenditures?
Generation Bio Co. (GBIO) invested $2.4M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Generation Bio Co. spend on research and development?
Generation Bio Co. (GBIO) invested $61.3M in research and development during fiscal year 2024.
How many shares does Generation Bio Co. have outstanding?
Generation Bio Co. (GBIO) had 7M shares outstanding as of fiscal year 2024.
What is Generation Bio Co.'s current ratio?
Generation Bio Co. (GBIO) had a current ratio of 5.50 as of fiscal year 2024, which is generally considered healthy.
What is Generation Bio Co.'s debt-to-equity ratio?
Generation Bio Co. (GBIO) had a debt-to-equity ratio of 1.68 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Generation Bio Co.'s return on assets (ROA)?
Generation Bio Co. (GBIO) had a return on assets of -57.0% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Generation Bio Co.'s cash runway?
Based on fiscal year 2024 data, Generation Bio Co. (GBIO) had $76.3M in cash against an annual operating cash burn of $88.6M. This gives an estimated cash runway of approximately 10 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Generation Bio Co.'s Piotroski F-Score?
Generation Bio Co. (GBIO) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Generation Bio Co.'s earnings high quality?
Generation Bio Co. (GBIO) has an earnings quality ratio of 0.67x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Generation Bio Co.?
Generation Bio Co. (GBIO) scores 50 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.